IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Amundi

Amundi reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 31.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 878,152 shares of the medical research company’s stock after selling 409,286 shares during the period. Amundi owned approximately 0.48% of IQVIA worth $179,424,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in IQVIA during the 4th quarter worth about $236,120,000. FMR LLC lifted its holdings in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in IQVIA in the third quarter valued at approximately $147,683,000. JPMorgan Chase & Co. increased its holdings in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares during the period. Finally, Nordea Investment Management AB raised its position in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IQV has been the topic of several recent research reports. Stephens started coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Citigroup lowered their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Price Performance

Shares of IQVIA stock opened at $191.69 on Monday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business has a 50 day simple moving average of $197.79 and a two-hundred day simple moving average of $212.63. The stock has a market capitalization of $33.80 billion, a P/E ratio of 25.56, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $261.72.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.